Evidence map›Paper›PMID 33979958›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2021

[Clinical efficacy and safety analysis of camrelizumab combined with apatinib as a second-line therapy for unresectable hepatocellular carcinoma: a multicenter retrospective study].

G S Yuan, W M He, X Y Hu, Q Li, M Y Zang, X Cheng, W Huang, J Ruan, J J Wang, J L Hou and 1 more

Open access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. [Chinese expert consensus on the use of standardized second-line drugs for primary hepatocellular carcinoma].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026
    Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

G S YuanDepartment of Infectious Diseases and Hepatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
W M HeDepartment of Infectious Diseases and Hepatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
X Y HuDepartment of Infectious Diseases and Hepatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Q LiDepartment of Infectious Diseases and Hepatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
M Y ZangDepartment of Infectious Diseases and Hepatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
X ChengDepartment of Hepatology, Zengcheng Branch of Nanfang Hospital, Southern Medical University, Zengcheng 511300, China.
W HuangDepartment of Oncology, Shunde Hospital, Southern Medical University, Shunde 528300, China.
J RuanDepartment of Medical Oncology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China.
J J WangDepartment of Infectious Disease, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, China.
J L HouDepartment of Infectious Diseases and Hepatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
J Z ChenDepartment of Infectious Diseases and Hepatology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Southern Medical University · CNSecond Affiliated Hospital of Guangzhou Medical University · CNThe First People's Hospital of Shunde · CNZhejiang Chinese Medical University · CN

Funding

Natural Science Foundation of Guangdong Province 2021A1515012518Special Fund for Clinical Research of Nanfang Hospital, Southern Medical University 2020CR019, 2020CR021
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAntibodies, Monoclonal, HumanizedHumansPyridinesRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedapatinibcamrelizumabPyridinesApatinibCamrelizumabEfficacyHepatocellular carcinomaSafety

Identifiers

PMID33979958
PMCPMC12814390
OpenAlexW3162289786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.